Global footprint BICO has a broad installed base with 53,600+ instruments across 65 countries and presence in over 3,500 laboratories, including top pharma players. This indicates strong recurring sales potential for consumables, software updates, and service agreements across multinational accounts.

Innovation platform The company emphasizes automation, intelligence, and data to accelerate discovery, powered by a global portfolio of pioneering brands. This presents cross-selling opportunities for integrated software, analytics, and automated lab workflows to pharma and biotech customers seeking scalable solutions.

Lifecycle depth With extensive citations in over 13,000 publications and long-term lab deployments, there is potential for expanding maintenance plans, training services, and upgrade cycles to extend product lifespans and maximize instrument utilization.

Public market Being listed on Nasdaq Stockholm under BICO provides visibility to institutional investors and potentially funding for expansion initiatives, which can be leveraged to secure larger enterprise deals and strategic partnerships.

Targeted partnerships Existing top-tier pharmaceutical and biotech lab footprints imply opportunities for co-development pilots, customized solutions, and early-access programs with major labs seeking to standardize on BICO platforms for efficiency gains.